2019 Volume 5 Issue 1 Pages 63-68
Currently, 13N-ammonia and Rubidium-82 (82Rb) are the only FDA-approved myocardial perfusion positron emission tomography (PET) tracers for myocardial perfusion imaging in the evaluation of suspected or known coronary artery disease (CAD), quantification of left ventricular volumes and systolic function and quantification of global and regional myocardial blood flow (MBF) and myocardial flow reserve (MFR). Nevertheless, there are physical, chemical and molecular differences between them. The ideal perfusion tracer would include 100% extraction from blood to tissue, and 100% retention, resulting in a linear relationship between MBF and the measured tracer activity over a wide range. However, both 13N-ammonia and 82Rb have limited characteristics. In this review, we aim to analyze 13N-ammonia in detail, and its differences with other radiotracers for the assessment of myocardial perfusion.